CO2024000294A2 - Composición que comprende cannabidiol e hidroxicloroquina en una cápsula combinada de dosis fija - Google Patents
Composición que comprende cannabidiol e hidroxicloroquina en una cápsula combinada de dosis fijaInfo
- Publication number
- CO2024000294A2 CO2024000294A2 CONC2024/0000294A CO2024000294A CO2024000294A2 CO 2024000294 A2 CO2024000294 A2 CO 2024000294A2 CO 2024000294 A CO2024000294 A CO 2024000294A CO 2024000294 A2 CO2024000294 A2 CO 2024000294A2
- Authority
- CO
- Colombia
- Prior art keywords
- cannabidiol
- hydroxychloroquine
- composition
- fixed
- dose combination
- Prior art date
Links
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 title abstract 4
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 title abstract 4
- 229950011318 cannabidiol Drugs 0.000 title abstract 4
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 title abstract 4
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 title abstract 3
- 229960004171 hydroxychloroquine Drugs 0.000 title abstract 3
- 239000002775 capsule Substances 0.000 title abstract 2
- 229940000425 combination drug Drugs 0.000 title 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000002552 dosage form Substances 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 239000011885 synergistic combination Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
COMPOSICIÓN QUE COMPRENDE CANNABIDIOL E HIDROXICLOROQUINA EN UNA CÁPSULA COMBINADA DE DOSIS FIJA RESUMEN La presente divulgación se refiere generalmente a composiciones que comprenden una combinación sinérgica de cannabidiol (CBD) o una sal o derivado farmacéuticamente aceptable del mismo e hidroxicloroquina o una sal farmacéuticamente aceptable de la misma, que permite de manera beneficiosa la administración simultánea de los dos ingredientes farmacéuticos activos (API) en un solo forma de dosificación. En una realización, la presente divulgación también se refiere a métodos y usos de la composición para el tratamiento de una afección inflamatoria. Sector: Química Subsector: Productos farmacéuticos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021902170A AU2021902170A0 (en) | 2021-07-15 | A composition and uses thereof | |
| PCT/AU2022/050731 WO2023283684A1 (en) | 2021-07-15 | 2022-07-13 | Composition comprising cannabidiol and hydroxychloroquine in a fixed dose combination capsule |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024000294A2 true CO2024000294A2 (es) | 2024-05-10 |
Family
ID=84918836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0000294A CO2024000294A2 (es) | 2021-07-15 | 2024-01-15 | Composición que comprende cannabidiol e hidroxicloroquina en una cápsula combinada de dosis fija |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4370209A1 (es) |
| AU (1) | AU2022309612A1 (es) |
| CA (1) | CA3224079A1 (es) |
| CO (1) | CO2024000294A2 (es) |
| IL (1) | IL309886A (es) |
| WO (1) | WO2023283684A1 (es) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9807639D0 (en) * | 1998-04-14 | 1998-06-10 | Kennedy Rheumatology Inst | Anti-inflammatory agents |
| CA2817879C (en) * | 2010-07-19 | 2020-03-24 | Procaps Sa | Apparatus and process for encapsulating capsules or other solid dosage forms within capsules |
| US20200009077A1 (en) * | 2018-07-03 | 2020-01-09 | TRUETIVA, Inc. | Compositions for treating dermatological diseases |
| WO2021195691A1 (en) * | 2020-04-02 | 2021-10-07 | Incannex Healthcare Limited | Methods and compositions for treating or preventing an inflammatory condition |
| AU2021103957A4 (en) * | 2021-07-07 | 2021-09-09 | Breathe Life Sciences Pty Ltd | A composition and application thereof |
-
2022
- 2022-07-13 WO PCT/AU2022/050731 patent/WO2023283684A1/en active Application Filing
- 2022-07-13 CA CA3224079A patent/CA3224079A1/en active Pending
- 2022-07-13 EP EP22840862.1A patent/EP4370209A1/en active Pending
- 2022-07-13 IL IL309886A patent/IL309886A/en unknown
- 2022-07-13 AU AU2022309612A patent/AU2022309612A1/en active Pending
-
2024
- 2024-01-15 CO CONC2024/0000294A patent/CO2024000294A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022309612A1 (en) | 2024-02-01 |
| WO2023283684A1 (en) | 2023-01-19 |
| EP4370209A1 (en) | 2024-05-22 |
| CA3224079A1 (en) | 2023-01-19 |
| IL309886A (en) | 2024-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dalmagro et al. | Involvement of PI3K/Akt/GSK-3β signaling pathway in the antidepressant-like and neuroprotective effects of Morus nigra and its major phenolic, syringic acid | |
| CL2016001411A1 (es) | Unidad de dosificación farmacéutica solida de desintegración oral que comprende un componente de estetrol; metodo de preparación; uso para la anticoncepción femenina y en terápia de sustitución hormonal femenina. | |
| AR060836A1 (es) | Un disco trans-mucosa para administrar un agente activo, una composicion trans-mucosa y el metodo de administracion obtenido | |
| KR20150112995A (ko) | 15-ohepa를 포함하는 조성물 및 그의 사용 방법 | |
| AR070026A1 (es) | Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus | |
| CO6640268A2 (es) | Formas de decodificación oral de bendamustina y su uso terapéutico | |
| CO2023002852A2 (es) | Péptidos funcionalizados como agentes antivirales | |
| DOP2011000195A (es) | Formulaciones de imiquimod de baja concentracion de dosis y regimenes de dosis de corta duracion para tratar queratosis actinica | |
| CO6260085A2 (es) | Composicion farmaceutica que contiene una combinacion sinergica de venotonicos y vasoprotectores | |
| CL2019003572A1 (es) | Combinaciones de brimonidina de dosis baja y usos de las mismas. | |
| AR061166A1 (es) | Composiciones farmaceuticas para la liberacion sostenida de fenilferina | |
| CL2019002172A1 (es) | Agente terapéutico para enfermedades del hígado. | |
| CL2021002107A1 (es) | Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria. | |
| CO2022017622A2 (es) | Inhibidores de quinasa nek7 | |
| CO6220945A2 (es) | Uso de una composicion que comprende formoterol y dipropianato de beclometasona para la prevencion y/o tratamiento de una exacerbacion de asma | |
| CO2022008437A2 (es) | Métodos de tratamiento del cáncer de pulmón de cé-lulas pequeñas con formulaciones de lurbinectedina | |
| AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
| AR033390A1 (es) | Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes | |
| CO2024000294A2 (es) | Composición que comprende cannabidiol e hidroxicloroquina en una cápsula combinada de dosis fija | |
| AR075866A1 (es) | Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica. | |
| BR112015012497A8 (pt) | combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial | |
| DOP2022000004A (es) | Composiciones farmacéuticas resistentes a la descarga de dosis que comprenden venirunad | |
| BR112022007616A2 (pt) | Métodos e composições para tratar doença falciforme com um inibidor de ferroportina (vit-2763) | |
| CO2018013792A2 (es) | Regímenes de dosificación de vortioxetina para el rápido inicio del efecto antidepresivo | |
| RU2013126798A (ru) | Комбинированная терапия дексаметазоном |